Linnea Cipriano
Partner in Goodwin's Intellectual Property Litigation practice in New York, specializing in life sciences patent litigation in federal courts and the USPTO's PTAB.
1
APPEARANCES
1
PODCASTS
Sep 15, 2026
Ritu BaralHOST
That's the question to ask, which of these patents are listed on the Orange Book? And that is how investors would approach assessing that.
Linnea CiprianoGUEST
So the Orange Book patents are going to be those that actually protect the drug product.
Linnea CiprianoGUEST
Now, and those are, I think, the advice to any pharmaceutical company is going to be to obtain as many of those as you can and that you can defensively list.
Linnea CiprianoGUEST
Now, layered in that is going to be potentially patents on the devices that are used within the Orange Book patents.